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INTRODUCTION: 
Sjögren’s syndrome (SS) is a chronic autoimmune disorder affecting approximately 0.1–0.4% of the 
general population with a female-to-male ratio of 9:1 usually diagnosed in the fourth and fifth decades of 
life [1]. Clinically, SS is typified by ocular and oral dryness developed as a consequence of the 
autoimmune process. It may occur either alone, as primary (p)SS, or secondary to other autoimmune 
disease, often rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or systemic sclerosis, 
secondary (s)SS. There is an increased risk of developing non-Hodgkin’s B cell lymphoma [2]. Altered B 
cell subpopulations have also been shown to correlate with disease activity [2]. CD4+ T helper (Th) cells 
play a crucial role in the pathogenesis of pSS. T cells were initially identified as the predominant cells 
within the salivary gland infiltrates and have been shown to be involved in the generation and 
perpetuation of inflammatory infiltrates in salivary glands in SS [3-4].  
 
Aims 
1.) Identify the peripheral B and T cells abnormalities in patients with pSS, secondary SS associated  with  
systemic lupus erythematosus (SLE)  and SLE alone in comparison to healthy donors. 
2.) Correlate immune phenotypes with clinical features and  serological parameters. 
3). Identify distinct patients’ endotypes relevant for therapeutic strategies. 
 
 
 
Table1:  Extensive  disease activity, clinical and serological characteristics of 
subjects groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD19+ B cells, CD4+ and CD8+ T cell subpopulations representative plots from 
peripheral blood mononuclear cells (PBMCs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS: 
RESULTS: 
 
1) Heat-maps showing distinct  CD19+ B cells, and CD4+ and CD8+ T cell 
subpopulations in pSS, SLE and SS/SLE patients compared to healthy donors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2) Volcano plots of significant positive and negative correlations of immune cells 
with clinical parameters in  pSS, SLE and  SS/SLE patients. 
 
 
 
 
 
 
 
 
 
 
 
 
3) Fold-change graphs of immune cells expression in patients comparison to 
healthy donors. 
 
 
 
 
 
 
 
 
 
 
 
 
4) Hierarchical clustering  of immune cells  in patients with pSS, SLE and SS/SLE 
found 5 distinct endotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group-specific hierarchical clustering  of immune cells  in patients with pSS, SLE and SS/SLE,   
group 1= light green, group 2 = cyan, group 3 = light red, group 4 = black and group 5 = gold. 
 
DISCUSSION/CONCLUSIONS: 
 
 
• This is the first comprehensive immunophenotype analysis performed patients with pSS, SLE and SS/SLE  
• We identified significant reduction in memory B cells fold-changed in all disease groups, reduction  in CD4+ naïve 
T cells in SLE and SS/SLE and reduction in T responders in all disease CD8+ in comparison to healthy donors. 
• The most significant T cell abnormalities were found in patients with SLE, however a significant correlation 
between lipid raft expression as marker of cell activation and disease activity score (ESSDAI) was found only in 
pSS patients. 
• SS/SLE have the most striking B cell phenotype abnormalities than patients with pSS or SLE (increased Bm2 
cells and decreased early and late Bm5 cells). 
• The five distinct disease endotype clustering showed distinct immune profile in patients with overlapping 
autoimmune conditions which is particularly relevant for stratification of therapy. 
Figure 1: Representative flow cytometry dotplots showing CD19+ B cells and CD4+/CD8+ T cell subpopulations.  
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 pSS (n=28) SLE (n=32) SS/SLE (n=15) Significance  
Disease duration, (years)  
mean (range) 
11 (3 -23) 17 (0.25 - 39) 24 ( 3 - 43) pSS vs. SS/SLE p***0.0007 
Positive salivary gland biopsy 
N (%) 
 
14 (50) n/a 7 (47) ns 
 
 
Disease scores and serology 
    ESSPRI SCORE, median 
[IQR] 
3 [3 - 6] 
 
n/a 5 [2  - 6] ns 
 
ESSDAI, median [IQR] 2 [0 - 3] n/a 2 [1  - 4] ns 
SSDDI, median [IQR] 1 [1 - 2] n/a 1 [0 - 1] ns 
Global BILAG, median [IQR] n/a 0 [0 - 2] 0 [0 - 1] ns 
Positive anti-Ro antibodies N 
(%) 
23 (82) 18 (56) 10 (67) 
ns 
Positive anti-La antibodies N 
(%) 
14 (50) 9 (28) 2 (15) ns 
 
RF N (%) 16 (57) 4 (13) 4 (27) ns 
Positive ANA N (%) 23 (82) 25 (78) 8 (53) ns 
Anti dsDNA N (%) 
0 (0) 18 (56) 6 (40) pSS vs. SLE p****0.0001,   
pSS  vs. SS/SLE p***0.0019 
Peak titer anti-dsDNA, mean 0 253 (2 -1338) 344 (3 - 1698) ns 
Positive anti-Sm N (%) 0 (0) 6 (19) 0 (0) ns 
Positive anti-RNP antibodies N 
(%) 
0 (0) 8 (25) 1 (7) pSS vs. SLE p*0.0473 
 
C3, g/L (normal  values 0.9-
1.8)  mean (range) 
1.2 (0.60 - 3.0) 
 
1.1 (0.65 - 1.58) 
 
1.0 (0.63 - 1.81) 
 
ns 
CRP, > 5 mg/l N (range)  2 (0.6 - 10.7) 8 (0.6 - 23.6) 3 (0.6 - 12.9) ns 
ESR, mm/hr  (normal range 0-
20), mean (range) 
14 (2 - 49) 27 (2 - 120) 26 (2 - 81) ns 
IgM, g/L (normal range 0.4-
2.3) mean (range) 
1.2 (0.42 - 3.38) 
 
1.1 (0.10 - 6.27) 
 
1.1 (0.40 - 1.83) 
 
ns 
IgG, g/L (normal range 7-16) 
mean (range) 
16.0 (6.87 - 27.86) 
 
12.8 (4.1 - 18.23) 
 
14.7 (9.53 - 33.7) 
 
ns 
 
IgG, > 20g/L N (%) 4 (14) 1 (3) 2 (13) ns 
Hb, g/L  (normal range 115-
155.) mean (range)  
125.3 (96 - 143) 118.9 (9.8 - 150) 104.6 (11.4 - 141) ns 
 
WBC, X10
3
/mm
3
 (normal 
range 3-10) , mean (range) 
5.6 (2.93 - 10.05) 7.0 (3.27 - 12.51) 7.5 (2.09 - 14.24) ns 
 
Lymphocytes, X 10
9
/L,  
(normal range 1.2-3.65)  mean 
(range) 
1.3 (0.53 - 2.69) 1.8 (0.49 - 6.81) 2.2 (0.80 - 4.17) ns 
 
 
Neutrophils, X 10
9
/L,  (normal 
range 2-7.5) mean (range) 
 
3.6 (1.0 - 7.86) 
 
 
4.5 (1.62 - 9.81) 
 
5.2 (0.99 - 12.52) 
 
pSS vs. SS/SLE p*0.0398  
 
Lipid profile     
N (%) patients with normal 
cholesterol  
9 (32) 13 (41) 11 (73) ns 
 
N (%) patients with abnormal 
triglycerides (>2.2) 
0 (0) 
 
4 (13) 
 
1 (7) 
 
ns 
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